Beam Therapeutics Inc.
25.175USD
-1.6550 (-6.17%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-1.17▲ | $-1.18 | 4 | 5 |
| Next quarter | $-1.19▲ | $-1.2 | 3 | 6 |
| Current year | $-4.45▲ | $-4.47 | 4 | 5 |
| Next year | $-4.74▲ | $-4.74 | 5 | 3 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-1.13 | $-1.18 | -0.05 (-4.8%) |
| 2026-03-31 | $-1.01 | $-0.91 | +0.10 (+10.1%) |
| 2025-12-31 | $-1.12 | $2.33 | +3.45 (+309.0%) |
| 2025-09-30 | $-1.01 | $-1.1 | -0.09 (-9.0%) |
90 ratings from 24 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Wedbush | Reiterated | Outperform | $65 | Sep 9, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $80 | Aug 25, 2026 |
| B of A Securities | Reiterated | Buy | $47 | Jul 8, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $80 | Jul 7, 2026 |
| Bernstein | Maintained | Outperform | $40 $39 | May 13, 2026 |
| Citigroup | Maintained | Buy | $64 $68 | Mar 26, 2026 |
| RBC Capital | Maintained | Sector Perform | $22 $26 | Feb 25, 2026 |
| Wedbush | Maintained | Outperform | $57 $65 | Feb 25, 2026 |
| Canaccord Genuity | Initiated | Buy | $74 | Feb 20, 2026 |
| Bernstein | Maintained | Outperform | $37 $41 | Jan 21, 2026 |
| UBS | Initiated | Neutral | $28 | Jan 7, 2026 |
| Evercore ISI Group | Initiated | Outperform | $35 | Nov 24, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $80 | Oct 10, 2025 |
| JP Morgan | Maintained | Overweight | $48 $46 | Oct 9, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $80 | Sep 15, 2025 |
| Barclays | Maintained | Equal-Weight | $25 $21 | Aug 6, 2025 |
| Guggenheim | Maintained | Buy | $78 $55 | May 7, 2025 |
| Wells Fargo | Maintained | Overweight | $75 $70 | May 7, 2025 |
| Barclays | Maintained | Equal-Weight | $31 $25 | May 7, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $80 | Apr 7, 2025 |
| B of A Securities | Upgraded from Neutral | Buy | $42 | Mar 28, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | — | Mar 12, 2025 |
| Scotiabank | Upgraded from Sector Perform | Sector Outperform | $40 | Mar 10, 2025 |
| Jones Trading | Upgraded from Hold | Buy | $34 | Mar 10, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $80 | Mar 10, 2025 |
64 filings from 7 insiders · 9 buy / 10 sell over 6m
Officers and directors of BEAM, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SIMON AMYOfficer | Sell | 16.7k | $25.74 | $429k | Jul 27, 2026 |
| EVANS JOHN M.Chief Executive Officer | Exercise | 50.0k | $0.67 | $45k | Jun 30, 2026 |
| SIMON AMYOfficer | Sell | 373 | $34.73 | $13k | Jun 30, 2026 |
| EVANS JOHN M.Chief Executive Officer | Sell | 50.0k | $34.26 | $1.75M | Jun 30, 2026 |
| FMR, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sellindirect | 284.9k | $35.12 | $10.04M | Jun 26, 2026 |
| CIARAMELLA GIUSEPPEPresident | Exercise | 35.5k | $0.67 | $34k | Jun 17, 2026 |
| CAVANAGH BETHANY JOfficer and Treasurer | Sell | 3.2k | $24.58 | $80k | Apr 1, 2026 |
| SIMON AMYOfficer | Sell | 6.7k | $24.58 | $165k | Apr 1, 2026 |
| BELLON CHRISTINEOfficer | Sell | 6.0k | $24.58 | $146k | Apr 1, 2026 |
| EVANS JOHN M.Chief Executive Officer | Sell | 30.1k | $24.58 | $739k | Apr 1, 2026 |
| CIARAMELLA GIUSEPPEPresident | Sell | 11.8k | $24.58 | $290k | Apr 1, 2026 |
| CAVANAGH BETHANY JOfficer and Treasurer | Grant | 20.0k | — | — | Mar 31, 2026 |
| SIMON AMYOfficer | Grant | 31.8k | — | — | Mar 31, 2026 |
| BELLON CHRISTINEOfficer | Grant | 20.0k | — | — | Mar 31, 2026 |
| EMANY SRAVAN KUMARChief Financial Officer | Grant | 31.8k | — | — | Mar 31, 2026 |
| EVANS JOHN M.Chief Executive Officer | Grant | 90.0k | — | — | Mar 31, 2026 |
| CIARAMELLA GIUSEPPEPresident | Grant | 40.0k | — | — | Mar 31, 2026 |
| EVANS JOHN M.Chief Executive Officer | Exercise | 50.0k | $0.67 | $34k | Mar 31, 2026 |
| EVANS JOHN M.Chief Executive Officer | Sell | 50.0k | $22.37 | $1.13M | Mar 31, 2026 |
| CIARAMELLA GIUSEPPEPresident | Exercise | 35.0k | $17.00 | $595k | Feb 24, 2026 |
No analyst notes on BEAM yet.
Analyst Ratings
13 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 12 | 2 | 0 | 0 | Buy2.07 |
| 1 mo ago | 1 | 12 | 2 | 0 | 0 | Buy2.07 |
| 2 mo ago | 1 | 12 | 2 | 0 | 0 | Buy2.07 |
| 3 mo ago | 1 | 14 | 2 | 0 | 0 | Buy2.06 |